July 14, 2015, COLOGNE, Germany—Axiogenesis AG, a leading supplier of tissue-specific human cell types derived from induced pluripotent stem cells (iPSCs), and provider of pre-clinical drug development assays and disease models, announced today that it has signed an sublicense agreement with GE Healthcare (GEHC). Under the agreement, GEHC will sublicense intellectual property to use human iPSCs, enabling Axiogenesis to develop cellular assays and models derived from stem cells for use in drug discovery and toxicity screening for its customers. This agreement strengthens Axiogenesis’ ability to offer the market freedom-to-operate with Axiogenesis’ proprietary iPSC-derived cells and tissues.
[Read more…]
“Blockbuster” Year for Induced Pluripotent Stem Cells Provides Expanding Opportunities, with Japan at the Forefront of Global Innovation
To create profitable products and services, stem cell industry executives need to stay informed about rapidly-evolving industry trends. For this reason, this post explores important trends, events, and metrics of importance within the induced pluripotent stem cell (iPSC) industry. It also considers geographical dominance within the industry.
[Read more…]
Market Share for Induced Pluripotent Stem Cell (iPSC) Research Products, by Product Category
Since their discovery in 2006, induced pluripotent stem cells (iPSCs) have been commercialized in a number of different ways. iPSCs have been used as tools for drug development and discovery, for toxicology applications, in stem cell biobanking, in personalized medicine, and as research products. While each of these commercial applications is important, this post specifically considers the use of iPSCs as research products – meaning, tools that scientists use in their labs for research purposes and applications.
Specifically, this post explores the breakdown of induced pluripotent stem cells (iPSCs) research products, by category. This analysis is intended to direct the decision-making of research supply companies by indicating where there is high market demand at this time. (To learn about future directions for iPSCs, click here.)
[Read more…]
The Market for Induced Pluripotent Stem Cell (iPSC) Research Products – Rate of Entrants, by Year
Are you an executive at a stem cell company that offers induced pluripotent stem cell (iPSC) research products? Or, are you an investor in a company of this type? If so, have you wondered how much market competition exists for your products or services? Have you been curious as to the rate at which this competition is increasing? By focusing on these key points of understanding, you’ll be able to assess the technical attributes that matter, including what opportunities exist for expanding your product line and your customer reach.
iPSC research products have existed since 2006, the year in which Shinya Yamanaka’s team at Kyoto University first produced iPSCs from mouse cells. The discovery was a vital advancement in stem cell research, as it allows researchers to obtain pluripotent stem cells without the difficult legal, technical and ethical controversies that have long surrounded deriving cells from embryos. Yamanaka and his team reprogrammed adult mouse fibroblasts into iPSCs by introducing four reprogramming factors: Oct4, Sox2, c-Myc and Klf4. Subsequent work by James Thomson and colleagues replicated Yamanaka’s success with human cells and revealed additional factors, Nanog and Lin28, which facilitate the reprogramming process.
[Read more…]
Induced Pluripotent Stem Cell News Round-Up| June 2015
Induced pluripotent stem cells (iPSCs) are a rapidly evolving area of stem cell science. Since the discovery of the cell type in 2006, there have been several important market events, including the first ever clinical trial in humans which launched in August of 2013 to evaluate the capacity of iPSC-derived cell sheets for their ability to restore vision in patients with wet-type macular degeneration. More recently, the Supreme Court rejected the right of the Wisconsin Alumni Research Foundation (WARF) to control patents related to iPSC derivation in a landmark patent decision issued in February 2015.
Every month there are major events occurring in the iPSC sector that shift industry dynamics. Read on to get informed about the most important iPSC market events as of June 2015. [Read more…]